Tags

Type your tag names separated by a space and hit enter

Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Drugs Today (Barc). 2010 May; 46(5):315-25.DT

Abstract

The sphingosine-1-phosphate receptor modulator fingolimod (FTY-720), which acts by preventing lymphocyte egress from lymph nodes thus reducing lymphocyte infiltration into the central nervous system (CNS), represents a novel therapeutic modality for the treatment of multiple sclerosis (MS). Results obtained from preclinical studies have also attributed a potential neuroprotective and reparative function to the agent within the CNS. Clinical evaluation in placebo-controlled trials in healthy individuals and MS patients revealed favorable safety and superior efficacy. Fingolimod was also reported to exhibit superiority, with respect to relapse rates and magnetic resonance imaging (MRI) outcomes, compared with the established MS therapeutic interferon beta-1a (IFN-beta-1a) in patients with relapsing-remitting MS in a 12-month clinical study. The oral route of administration of fingolimod renders it a more convenient therapeutic option than intramuscular IFN-beta-1a, while its lipophilicity which permits ready crossing of the blood-brain-barrier may result in enhanced activity. The positive risk-to-benefit profile of the agent supports the once-daily administration regimen for the treatment of MS.

Authors+Show Affiliations

Thomson Reuters, Barcelona, Spain. sylvia.vasiliou@thomsonreuters.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20517533

Citation

Vasiliou, S. "Oral Fingolimod for the Treatment of Relapsing-remitting Multiple Sclerosis." Drugs of Today (Barcelona, Spain : 1998), vol. 46, no. 5, 2010, pp. 315-25.
Vasiliou S. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drugs Today. 2010;46(5):315-25.
Vasiliou, S. (2010). Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drugs of Today (Barcelona, Spain : 1998), 46(5), 315-25. https://doi.org/10.1358/dot.2010.46.5.1497556
Vasiliou S. Oral Fingolimod for the Treatment of Relapsing-remitting Multiple Sclerosis. Drugs Today. 2010;46(5):315-25. PubMed PMID: 20517533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. A1 - Vasiliou,S, PY - 2010/6/3/entrez PY - 2010/6/3/pubmed PY - 2010/8/20/medline SP - 315 EP - 25 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today VL - 46 IS - 5 N2 - The sphingosine-1-phosphate receptor modulator fingolimod (FTY-720), which acts by preventing lymphocyte egress from lymph nodes thus reducing lymphocyte infiltration into the central nervous system (CNS), represents a novel therapeutic modality for the treatment of multiple sclerosis (MS). Results obtained from preclinical studies have also attributed a potential neuroprotective and reparative function to the agent within the CNS. Clinical evaluation in placebo-controlled trials in healthy individuals and MS patients revealed favorable safety and superior efficacy. Fingolimod was also reported to exhibit superiority, with respect to relapse rates and magnetic resonance imaging (MRI) outcomes, compared with the established MS therapeutic interferon beta-1a (IFN-beta-1a) in patients with relapsing-remitting MS in a 12-month clinical study. The oral route of administration of fingolimod renders it a more convenient therapeutic option than intramuscular IFN-beta-1a, while its lipophilicity which permits ready crossing of the blood-brain-barrier may result in enhanced activity. The positive risk-to-benefit profile of the agent supports the once-daily administration regimen for the treatment of MS. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/20517533/Oral_fingolimod_for_the_treatment_of_relapsing_remitting_multiple_sclerosis_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=1497556 DB - PRIME DP - Unbound Medicine ER -